Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mendus Yönetim

Yönetim kriter kontrolleri 2/4

Mendus' CEO'su Erik Manting, Mar2021 tarihinde atandı, in görev süresi 3.58 yıldır. şirketin hisselerinin 0.46% doğrudan sahiptir ve bu hisselerin değeri € 164.29K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 3.3 yıldır.

Anahtar bilgiler

Erik Manting

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.6yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Erik Manting (53 yo)

3.6yrs

Görev süresi

Dr. Erik Manting, Ph D., has been the Chief Executive Officer at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Exec...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Erik Manting	Chief Executive Officer	3.6yrs	Veri yok	0.46% SEK 162.1k
Alex Karlsson-Parra	Co-Founder & Chief Scientific Officer	16.8yrs	SEK 1.42m	Veri yok
Lotta Ferm	Chief Financial Officer	3.7yrs	Veri yok	0.20% SEK 69.5k
Leopold Bertea	Chief Technology Officer	2.4yrs	Veri yok	Veri yok
Jeroen Rovers	Chief Medical Officer	no data	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 1YG0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ada Kruisbeek	Chair of Scientific Advisory Board	3.1yrs	Veri yok	Veri yok
Sven Andreasson	Independent chairman	4.5yrs	SEK 325.00k	Veri yok
Lewis Lanier	Member of Scientific Advisory Board	1.3yrs	Veri yok	Veri yok
Hans Preusting	Independent Director	3.4yrs	SEK 330.00k	Veri yok
Helen Tuvesson	Independent Director	4.5yrs	SEK 355.00k	Veri yok
Tanja de Gruijl	Member of Scientific Advisory Board	3.1yrs	Veri yok	Veri yok
Dharminder Chahal	Independent Director	3.8yrs	SEK 355.00k	0.44% SEK 153.2k
Inge Svane	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Sjoerd van Burg	Member of Scientific Advisory Board	3.1yrs	Veri yok	Veri yok
Ted Fjallman	Independent Director	less than a year	SEK 285.00k	Veri yok

3.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1YG0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Mendus Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB (publ), Annual General Meeting, May 17, 2024

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

High number of new and inexperienced directors

Recent updates

No longer forecast to breakeven

Now 24% overvalued

Forecast to breakeven in 2025

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

New major risk - Financial position

Mendus AB (Publ) Announces Clinical Pipeline Update

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Mendus AB (publ), Annual General Meeting, May 17, 2024

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Forecast to breakeven in 2023

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought €241k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

New 90-day low: €0.67

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

Independent Chairman Michael S. Oredsson has left the company

Immunicum AB (Publ) Announces Executive Changes

Immunicum AB (publ) Approves Election of New Board Members

Immunicum AB (publ) Announces Transitions in Board of Directors

New 90-day low: €0.70

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Immunicum AB (publ) Announces Changes to the Nomination Committee

Immunicum AB (publ) (OM:IMMU) completed the acquisition of DCPrime B.V. from Van Herk Investments B.V. and others.

Immunicum AB (Publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial

Immunicum AB (publ) to Report First Half, 2021 Results on Aug 26, 2021

Immunicum AB (publ) (OM:IMMU) entered into a share purchase agreement to acquire DCPrime B.V. from Van Herk Investments B.V. and others for €58.8 million.

Immunicum AB (Publ) Announces Appointment of Hans Derninger to the Nomination Committee

Immunicum AB (publ) Announces Nomination Committee

Immunicum AB (publ), Annual General Meeting, May 04, 2021

New 90-day low: €0.77

Immunicum AB Announces Resignation of Magnus Persson from its Board of Directors